β-Spaglumic acid_product_DataBase

Bioactivity	β-Spaglumic acid (β-NAAG) is a competitive NAAG peptidase inhibitor (Ki=1 µM) that protects spinal cord neurons from excitotoxicity and hypoxic damage. β-Spaglumic acid is also a selective mGluR3 antagonist (mGluR3 receptor functions to regulate activity-dependent synaptic potentiation in the hippocampus). β-Spaglumic acid can be used in neuroprotection-related studies[1][2].
Target	NAAG peptidase, mGluR3.
Invitro	β-Spaglumic acid (63-1000 µM; 2 h) protects against NMDA-induced injury of spinal cord cells in a dose-dependent manner[1].β-Spaglumic acid (0-1000 µM; 2 h) protects spinal cord cells against hypoxia[1].β-Spaglumic acid (500 µM) significantly reduces intraneuronal free Ca2+ responses upon neuronal exposure to 25 µM NMDA[1].β-Spaglumic acid (100 µM; 7 min) antagonizes mGluR3 in cerebellar granule cells[2]. Cell Viability Assay[1] Cell Line:
Name	β-Spaglumic acid
CAS	4910-46-7
Formula	C11H16N2O8
Molar Mass	304.25
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Yourick DL, et al. N-acetylaspartylglutamate and beta-NAAG protect against injury induced by NMDA and hypoxia in primary spinal cord cultures. Brain Res. 2003 Nov 21;991(1-2):56-64. [2]. Wroblewska B, et al. β-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor. J Neurophysiol. 2001 Mar;85(3):1097-106.

PeptideDB